Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883240 · ClinicalTrials.gov registry record
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
A clinical trial of Von Willebrand Disease, Type 3, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- 40
- Enrollment target
- 20
- Study locations
NCT06883240 is a study of Von Willebrand Disease, Type 3 that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 40 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06883240, a study of Von Willebrand Disease, Type 3, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy per local standard of care (SOC) over an observation period of at least 24 weeks.
Conditions Studied
Interventions
- DRUG Von Willebrand Factor Concentrates
- DRUG Von Willebrand Factor Concentrates and Factor VIII Concentrates
- DRUG Factor VIII Concentrates
- DRUG Recombinant Activated Factor VII
- DRUG Activated Prothrombin Complex Concentrate
Study Locations (20)
Other
- UZ Leuven Gasthuisberg - Leuven
- IPS SURA Industriales Medellín - Medellín
- Hopital Claude Huriez - CHU Lille - Lille
- Groupe Hospitalier Necker Enfants Malades - Paris
- Universitätsklinikum Bonn - Bonn
- Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz - Duisburg
- Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin - Frankfurt/M.
- Kurume University Hospital - Fukuoka
- Tokyo Medical University Hospital - Tokyo
- Erasmus MC - Rotterdam
- Instytut Hematologii i Transfuzjologii - Warsaw
California
- UC Davis - Sacramento
Florida
- University of Florida - Gainesville
Minnesota
- University of Minnesota Medical Center - Minneapolis
Missouri
- Washington University School of Medicine - St Louis
Ontario
- The Hospital for Sick Children - Toronto
Quebec
- McGill University Health Center - Montreal
Lazio
- Universita' Degli Studi La Sapienza-Ist.Di Ematologia - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06883240
The ClinicalTrials.gov registry entry for NCT06883240 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Von Willebrand Disease, Type 3 appearing as the primary indexed condition, and to 5 interventions - of which Von Willebrand Factor Concentrates is the first listed.
NCT06883240 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06883240 about?
NCT06883240 is a clinical study titled "An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment". This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy...
What is the current status of trial NCT06883240?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2025-04-29. Estimated completion is 2026-11-01.
What conditions does trial NCT06883240 study?
This clinical trial studies the following conditions: Von Willebrand Disease, Type 3.
What interventions are being tested in trial NCT06883240?
The interventions under investigation include: Von Willebrand Factor Concentrates (DRUG), Von Willebrand Factor Concentrates and Factor VIII Concentrates (DRUG), Factor VIII Concentrates (DRUG), Recombinant Activated Factor VII (DRUG), Activated Prothrombin Complex Concentrate (DRUG).
Who is sponsoring clinical trial NCT06883240?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883240 being conducted?
This trial has 20 study locations across California, Florida, Minnesota, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease, Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.